TY  - JOUR
AU  - Dai Si-jie
AU  - Shao Yu-ying
AU  - Zheng Yang
AU  - Sun Jin-yi
AU  - Li Zhi-sheng
AU  - Shi Jia-ying
AU  - Yan Meng-qi
AU  - Qiu Xiao-yun
AU  - Xu Ceng-lin
AU  - Cho Wan-sang
AU  - Nishibori Masahiro
AU  - Yi Sihyeong
AU  - Park Seung Bum
AU  - Wang Yi
AU  - Chen Zhong
PY  - 2023
TI  - Inflachromene attenuates seizure severity in mouse epilepsy models via inhibiting HMGB1 translocation
JF  - Acta Pharmacologica Sinica; Vol 44, No 9 (September 2023): Acta Pharmacologica Sinica
Y2  - 2023
KW  - 
N2  - Epilepsy is not well controlled by current anti-seizure drugs (ASDs). High mobility group box 1 (HMGB1) is a DNA-binding protein in the nucleus regulating transcriptional activity and maintaining chromatin structure and DNA repair. In epileptic brains, HMGB1 is released by activated glia and neurons, interacting with various receptors like Toll-like receptor 4 (TLR4) and downstream glutamatergic NMDA receptor, thus enhancing neural excitability. But there is a lack of small-molecule drugs targeting the HMGB1- related pathways. In this study we evaluated the therapeutic potential of inflachromene (ICM), an HMGB-targeting small-molecule inhibitor, in mouse epilepsy models. Pentylenetetrazol-, kainic acid- and kindling-induced epilepsy models were established in mice. The mice were pre-treated with ICM (3, 10 mg/kg, i.p.). We showed that ICM pretreatment significantly reduced the severity of epileptic seizures in all the three epilepsy models. ICM (10 mg/kg) exerted the most apparent anti-seizure effect in kainic acid- induced epileptic status (SE) model. By immunohistochemical analysis of brain sections from kainic acid-induced SE mice, we found that kainic acid greatly enhanced HMGB1 translocation in the hippocampus, which was attenuated by ICM pretreatment in subregion- and cell type-dependent manners. Notably, in CA1 region, the seizure focus, ICM pretreatment mainly inhibited HMGB1 translocation in microglia. Furthermore, the anti-seizure effect of ICM was related to HMGB1 targeting, as pre-injection of anti- HMGB1 monoclonal antibody (5 mg/kg, i.p.) blocked the seizure-suppressing effect of ICM in kainic acid-induced SE model. In addition, ICM pretreatment significantly alleviated pyramidal neuronal loss and granule cell dispersion in kainic acid-induced SE model. These results demonstrate that ICM is an HMGB-targeting small molecule with anti-seizure potential, which may help develop a potential drug for treating epilepsy.
UR  - http://www.chinaphar.com/article/view/10882